Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839944 | 0.97 | NMBR (0.46) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL29759585 | 0.91 | NMBR (0.47) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL13227674 | 0.90 | MDM4 (0.54) | MDM4TP53SIRT2 | |
| SCHEMBL30433831 | 0.90 | MDM4 (0.54) | MDM4TP53SIRT2 | |
| SCHEMBL29368020 | 0.90 | MDM4 (0.54) | MDM4TP53SIRT2 | |
| SCHEMBL12994493 | 0.90 | MDM4 (0.54) | MDM4TP53SIRT2 | |
| SCHEMBL1737899 | 0.90 | MDM4 (0.54) | MDM4TP53SIRT2 | |
| SCHEMBL30468161 | 0.88 | SIRT2 (0.55) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL30385679 | 0.88 | MDM4 (0.49) | NMBRMDM4TP53SIRT2 | |
| SCHEMBL28913050 | 0.87 | SIRT2 (0.49) | NMBRMDM4TP53SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774838-B9 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-3774838-B2 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-06-12 | — | — | US | disclosed |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-02-13 | — | — | US | disclosed |
| CN-112543763-B | Method for cleaving solid phase binding peptide from solid phase | 赛诺菲-安万特德国有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-112218876-B | Rixila Synthesis with end capping | 赛诺菲-安万特德国有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2023-09-26 | — | — | US | disclosed |
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-08-03 | — | — | US | disclosed |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-06-08 | — | — | US | disclosed |
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3774838-B1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | VIP, PTMS, CTRC | NMBR 836/4885MDM4 4329/4885TP53 1190/4885 |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885MDM4 4715/4885TP53 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.